Q: What is Ilumya used for?

Ilumya is used to treat plaque psoriasis .

Q: How does Ilumya work?

Mechanism of Action Ilumya (tildrakizumab-asmn) is a monoclonal antibody that belongs to a class of medications known as interleukin inhibitors. It is designed to target and block a specific protein in the body called interleukin-23 (IL-23). In a healthy body, IL-23 is a cytokine—a chemical messenger—that helps regulate the immune system's response to infection. However, in people with moderate-to-severe plaque psoriasis, the body produces an excess of IL-23. This overabundance triggers an overactive immune response, leading to: Chronic inflammation within the skin. An accelerated life cycle of skin cells, which causes them to build up rapidly on the surface and form thick, scaly plaques. Ilumya works by binding specifically to the p19 subunit of the IL-23 protein. By doing so, it prevents IL-23 from attaching to its receptors on the surface of immune cells. This action interrupts the inflammatory signaling pathway, which helps to normalize the immune response, reduce skin inflammation, and slow down the excessive production of skin cells. Over time, this process helps clear existing plaques and prevents new ones from forming.

Q: What are the active ingredients in Ilumya?

The active ingredient in Ilumya is tildrakizumab .

Q: What are the side effects of Ilumya?

Common side effects of Ilumya may include: upper respiratory infection injection site reactions fatigue Always consult with a healthcare professional about potential side effects.

Q: What drug class is Ilumya?

Ilumya belongs to the IL-23 inhibitor drug class.

Q: What is the dosage of Ilumya and how do I take it?

Administration Ilumya is given as a subcutaneous injection, which means it is injected into the fatty tissue just under the skin. A healthcare professional usually administers this medication in a clinical setting, such as a doctor's office. Common injection sites include: The abdomen The front of the thighs The outer area of the upper arms The person giving the injection should avoid skin areas that are tender, bruised, red, or hard. They should also avoid injecting directly into areas of skin affected by psoriasis. Dosing Schedule The treatment typically begins with two initial doses spaced a few weeks apart. After these starting doses, the medication is usually administered once every few months as a maintenance schedule to manage symptoms over the long term. Missed Dose If you miss an appointment for your injection, contact your healthcare provider as soon as possible to reschedule. They will provide guidance on when to receive your next dose to keep your treatment on track.

Q: Is Ilumya safe during pregnancy and breastfeeding?

Pregnancy Data regarding the use of Ilumya in pregnant women is limited. While animal studies have not shown evidence of harm to a developing fetus at high doses, these results do not always predict how the drug will affect humans. Because Ilumya is a monoclonal antibody, it is expected to cross the placenta, particularly during the third trimester of pregnancy. Healthcare providers typically recommend using this medication during pregnancy only if the potential benefit justifies the potential risk to the fetus. If you are pregnant or planning to become pregnant, consult your doctor to discuss your treatment options. Breastfeeding It is currently unknown whether Ilumya passes into human breast milk or if it has any effect on a nursing infant or milk production. Because many drugs are excreted in human milk, caution is advised. Individuals who are breastfeeding or planning to breastfeed should talk with their healthcare provider to weigh the benefits of breastfeeding against the potential risks of the medication.

Q: What forms and strengths does Ilumya come in?

Available Forms Ilumya is supplied as a liquid solution for subcutaneous injection. It is available in the following delivery format: Single-dose prefilled syringe: This device is intended for one-time use and is administered by a healthcare professional. The medication is injected into the fatty tissue just beneath the skin, typically in areas such as the abdomen, thighs, or upper arms.

Q: What is the FDA approval status of Ilumya?

FDA Approval History The U.S. Food and Drug Administration (FDA) approved Ilumya on March 21, 2018. It was approved as a humanized interleukin-23 (IL-23) antagonist for the treatment of chronic skin conditions. Approved Indications Ilumya is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for: Systemic therapy (medications that work throughout the body) Phototherapy (light treatments) Regulatory Status Ilumya is a prescription-only medication. At this time, the FDA does not require a Boxed Warning or a Risk Evaluation and Mitigation Strategy (REMS) for this drug. It is administered by a healthcare professional via subcutaneous injection.

Question 1

What is Ilumya?

Accepted Answer

Ilumya is a monoclonal antibody that works by selectively binding to interleukin-23, a naturally occurring protein involved in the body's inflammatory response. By blocking this protein, the medication helps to regulate the overactive immune signals that contribute to inflammation.

Question 2

What is Ilumya used for?

Accepted Answer

Ilumya is used to treat plaque psoriasis.

Question 3

How does Ilumya work?

Accepted Answer

Mechanism of Action

Ilumya (tildrakizumab-asmn) is a monoclonal antibody that belongs to a class of medications known as interleukin inhibitors. It is designed to target and block a specific protein in the body called interleukin-23 (IL-23).

In a healthy body, IL-23 is a cytokine—a chemical messenger—that helps regulate the immune system's response to infection. However, in people with moderate-to-severe plaque psoriasis, the body produces an excess of IL-23. This overabundance triggers an overactive immune response, leading to:

Chronic inflammation within the skin.
An accelerated life cycle of skin cells, which causes them to build up rapidly on the surface and form thick, scaly plaques.

Ilumya works by binding specifically to the p19 subunit of the IL-23 protein. By doing so, it prevents IL-23 from attaching to its receptors on the surface of immune cells. This action interrupts the inflammatory signaling pathway, which helps to normalize the immune response, reduce skin inflammation, and slow down the excessive production of skin cells. Over time, this process helps clear existing plaques and prevents new ones from forming.

Question 4

What are the active ingredients in Ilumya?

Accepted Answer

The active ingredient in Ilumya is tildrakizumab.

Question 5

What are the side effects of Ilumya?

Accepted Answer

Common side effects of Ilumya may include:

upper respiratory infection
injection site reactions
fatigue

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Ilumya?

Accepted Answer

Ilumya belongs to the IL-23 inhibitor drug class.

Question 7

What is the dosage of Ilumya and how do I take it?

Accepted Answer

Administration

Ilumya is given as a subcutaneous injection, which means it is injected into the fatty tissue just under the skin. A healthcare professional usually administers this medication in a clinical setting, such as a doctor's office.

Common injection sites include:

The abdomen
The front of the thighs
The outer area of the upper arms

The person giving the injection should avoid skin areas that are tender, bruised, red, or hard. They should also avoid injecting directly into areas of skin affected by psoriasis.

Dosing Schedule

The treatment typically begins with two initial doses spaced a few weeks apart. After these starting doses, the medication is usually administered once every few months as a maintenance schedule to manage symptoms over the long term.

Missed Dose

If you miss an appointment for your injection, contact your healthcare provider as soon as possible to reschedule. They will provide guidance on when to receive your next dose to keep your treatment on track.

Question 8

Is Ilumya safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Data regarding the use of Ilumya in pregnant women is limited. While animal studies have not shown evidence of harm to a developing fetus at high doses, these results do not always predict how the drug will affect humans. Because Ilumya is a monoclonal antibody, it is expected to cross the placenta, particularly during the third trimester of pregnancy.

Healthcare providers typically recommend using this medication during pregnancy only if the potential benefit justifies the potential risk to the fetus. If you are pregnant or planning to become pregnant, consult your doctor to discuss your treatment options.

Breastfeeding

It is currently unknown whether Ilumya passes into human breast milk or if it has any effect on a nursing infant or milk production. Because many drugs are excreted in human milk, caution is advised. Individuals who are breastfeeding or planning to breastfeed should talk with their healthcare provider to weigh the benefits of breastfeeding against the potential risks of the medication.

Question 9

What forms and strengths does Ilumya come in?

Accepted Answer

Available Forms

Ilumya is supplied as a liquid solution for subcutaneous injection. It is available in the following delivery format:

Single-dose prefilled syringe: This device is intended for one-time use and is administered by a healthcare professional.

The medication is injected into the fatty tissue just beneath the skin, typically in areas such as the abdomen, thighs, or upper arms.

Question 10

What is the FDA approval status of Ilumya?

Accepted Answer

FDA Approval History

The U.S. Food and Drug Administration (FDA) approved Ilumya on March 21, 2018. It was approved as a humanized interleukin-23 (IL-23) antagonist for the treatment of chronic skin conditions.

Approved Indications

Ilumya is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for:

Systemic therapy (medications that work throughout the body)
Phototherapy (light treatments)

Regulatory Status

Ilumya is a prescription-only medication. At this time, the FDA does not require a Boxed Warning or a Risk Evaluation and Mitigation Strategy (REMS) for this drug. It is administered by a healthcare professional via subcutaneous injection.

Question 11

What should I know about Ilumya and cost?

Accepted Answer

Insurance and Out-of-Pocket Costs

The price you pay for Ilumya depends largely on your health insurance plan. Most commercial insurance plans, Medicare, and Medicaid provide some level of coverage for this medication. However, your specific out-of-pocket costs will be determined by your plan's deductible, copayments, or coinsurance requirements. Because Ilumya is a biologic medication, it is often processed through a medical benefit rather than a pharmacy benefit.

Administration Fees

Ilumya is administered by a healthcare professional in a medical office or clinic. Consequently, the total cost of treatment may include fees for the office visit and the professional administration of the injection, in addition to the cost of the drug itself.

Financial Assistance Programs

There are options available to help manage the cost of Ilumya for eligible patients:

Copay Savings Cards: Patients with commercial insurance may be eligible for manufacturer programs that reduce out-of-pocket costs to a minimal amount.
Patient Assistance: For individuals who are uninsured or have limited financial resources, programs may be available to provide the medication at no cost or a reduced rate.
Support for Government Insurance: Patients with Medicare or other government-funded insurance may need to seek assistance through independent charitable foundations if they face high costs.

At this time, there are no biosimilar versions of Ilumya available. Biosimilars are typically lower-cost alternatives to biologic drugs, but until one is approved and released, the brand-name medication remains the only option for this specific therapy.

Ilumya

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Ilumya

Hospitals.net Disclosure